CG Oncology (CGON) drew fresh attention after releasing Phase 2 CORE-008 Cohort CX data, which showed high complete response rates and high-grade event-free survival in high-risk, BCG-exposed and BCG-unresponsive non-muscle invasive bladder cancer.

The latest CORE-008 Phase 2 data arrives after a strong run, with the stock showing a 60.16% year to date share price return and a 163.19% 1 year total shareholder return, despite recent short term share price weakness, including a 1 day share price decline of 3.75% and a 30 day share price decline of 8.85%.

If this kind of clinical and share price momentum has your attention, it can be worth scanning for other high growth healthcare and biotech opportunities, including 32 healthcare AI stocks

With CG Oncology now valued at about US$5.9b and the stock trading at US$66.93, the key question is whether today’s price still leaves room for upside or if the market is already pricing in much of the future growth.

Preferred Price-to-Book of 5.4x: Is it justified?

On a P/B basis, CG Oncology trades at 5.4x book value. This sits between being cheaper than certain peers and richer than the broader US biotech group.

The P/B multiple compares the stock price with the company’s net assets per share. It is often used for early stage or loss making biopharma companies where earnings are not yet a reliable gauge.

According to Simply Wall St data, CG Oncology is described as good value versus a peer group average P/B of 22.3x, which suggests the stock is priced lower than some direct comparables relative to book value. At the same time, the company is described as expensive versus the wider US Biotechs industry average P/B of 2.4x, meaning the market assigns a richer valuation than it does to the typical listed biotech stock.

Result: Price-to-book of 5.4x (ABOUT RIGHT)

However, the story could shift quickly if key cretostimogene trials disappoint or if the company’s ongoing net loss of US$186.745m grows faster than expected.

Another view: DCF points to a very different story

While the 5.4x P/B ratio suggests CG Oncology sits between rich and cheap compared with peers and the wider biotech group, the SWS DCF model paints a far more aggressive picture. It indicates the stock is trading about 81% below its estimated fair value of $351.97. Which lens do you trust when the gap is this wide?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CG Oncology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Balancing strong data and a punchy valuation is rarely straightforward, so it makes sense to review the full picture quickly and compare your own thesis with the stock’s specific 3 key rewards and 1 important warning sign

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at a single stock. Broaden your watchlist with focused ideas that match your goals.

• Target potential value opportunities by checking out 51 high quality undervalued stocks that combine quality fundamentals with appealing pricing.
• Prioritise resilience by scanning 65 resilient stocks with low risk scores that score well on stability and lower overall risk.
• Spot potential future standouts by reviewing the screener containing 21 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.